Reviewing OPKO Health Inc. (OPK)’s and NantKwest Inc. (NASDAQ:NK)’s results – FinanceMercury

OPKO Health Inc. (NASDAQ:OPK) and NantKwest Inc. (NASDAQ:NK) have been rivals in the Biotechnology for quite some time. Below is a review of each business including various aspects such as risk, analyst recommendations, profitability, institutional ownership, dividends, earnings and valuation.

Valuation and Earnings

We can see in table 1 the earnings per share, gross revenue and valuation of OPKO Health Inc. and NantKwest Inc.

Profitability

Table 2 provides OPKO Health Inc. and NantKwest Inc.s return on equity, net margins and return on assets.

Risk & Volatility

A 2.13 beta indicates that OPKO Health Inc. is 113.00% more volatile compared to Standard and Poors 500. NantKwest Inc. on the other hand, has 2.34 beta which makes it 134.00% more volatile compared to Standard and Poors 500.

Liquidity

The Current Ratio and Quick Ratio of OPKO Health Inc. are 1.1 and 1 respectively. Its competitor NantKwest Inc.s Current Ratio is 4.1 and its Quick Ratio is 4.1. NantKwest Inc. can pay off short and long-term obligations better than OPKO Health Inc.

Insider & Institutional Ownership

The shares of both OPKO Health Inc. and NantKwest Inc. are owned by institutional investors at 26.4% and 8.5% respectively. Insiders held roughly 5.5% of OPKO Health Inc.s shares. Comparatively, NantKwest Inc. has 21.5% of its share held by insiders.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

For the past year OPKO Health Inc. had bearish trend while NantKwest Inc. had bullish trend.

Summary

On 7 of the 10 factors OPKO Health Inc. beats NantKwest Inc.

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, and Mexico. The companys Diagnostics segment operates Bio-Reference Laboratories, a clinical laboratory that offers laboratory testing services in the detection, diagnosis, evaluation, monitoring, and treatment of diseases. The Bio-Reference Laboratories also provides core genetic testing and leverage products, such as the 4Kscore prostate cancer test and the Claros 1 in-office immunoassay platform. The companys pharmaceutical segment offers Rayaldee, a treatment for secondary hyperparathyroidism in adults with stage 3-4 chronic kidney disease patients with vitamin D deficiency; and VARUBI for chemotherapy-induced nausea and vomiting. This segment is also developing TT401, which is in Phase II clinical trials for type 2 diabetes and obesity; TT701, an androgen receptor modulator that is in Phase II clinical trials for androgen deficiency indications; and hGH-CTP, a growth hormone injection that is in Phase III clinical trials. In addition, it engages in developing and commercializing hGH-CTP, a recombinant human growth hormone product that is in Phase III; developing Factor VIIa drug for hemophilia that is in Phase IIa, an NK-1 compound, and drugs for treating asthma and chronic obstructive pulmonary disease; developing and producing specialty active pharmaceutical ingredients; and discovery of drugs for the treatment of cancer, heart disease, metabolic disorders, and a range of genetic anomalies. Further, this segment engages in the development, manufacture, and sale of pharmaceutical, nutraceutical, and veterinary products; and markets and distributes pharmaceutical and natural products. Additionally, OPKO Health, Inc. operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was incorporated in 1991 and is headquartered in Miami, Florida.

NantKwest, Inc., a clinical-stage immunotherapy biotechnology company, develops immunotherapeutic treatments for cancer, infectious diseases, and inflammatory diseases in the United States. The company develops activated natural killer product candidates for the treatment of virally-induced cancers, such as polyoma virus induced merkel cell carcinoma, human papilloma virus induced cervical, and head and neck cancers; infectious diseases, including Ebola; and other serious viral, fungal, and bacterial infections. It is also develops high-affinity natural killer product candidates primarily for the treatment of solid tumors, breast cancer, head and neck/squamous, lymphoma, and various cancer; and target activated natural killer product candidates to treat hematological malignancies and solid tumors. NantKwest, Inc. has a co-development agreement with Altor Bio Science Corporation to collaborate on the development of therapeutic applications combining the companys proprietary natural killer cells with Altor's ALT-801 and/or ALT-803 products. The company was formerly known as Conkwest, Inc. and changed its name to NantKwest, Inc. in July 2015. NantKwest, Inc. was founded in 2002 and is headquartered in San Diego, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Continued here:
Reviewing OPKO Health Inc. (OPK)'s and NantKwest Inc. (NASDAQ:NK)'s results - FinanceMercury